In the industry’s words – New Zealand’s MTANZ
This article was originally published in Clinica
New Zealand’s healthcare system is undergoing reforms likely to impact on procurement policy. The Medical Technology Association of New Zealand (MTANZ), while recognising the need for efficiency, believes it is critical that innovation does not become a victim of the current drive to contain costs – not least because of the NZ medtech industry’s focus on the export market. Here, Angela Pantano, business development manager for MTANZ’s Emerging Medical Technologies Group details some of the initiatives underway to “help develop and grow this vital part of the economy”
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.